RNA-seq analysis of the whole transcriptome of MDA-MB-231 mammary carcinoma cells exposed to the antimetastatic drug NAMI-A.

Gene expression profiling has been introduced into drug development to understand the activity of chemical entities in pre-clinical settings. The present study investigates the changes induced in gene expression by the ruthenium-based compound NAMI-A. The genes differentially expressed by NAMI-A are evaluated through whole-transcriptome analysis and RNA-sequencing in the metastatic MDA-MB-231 mammary carcinoma cells, in comparison to the non-tumorigenic HBL-100 mammary gland cells. NAMI-A treatment rapidly induces a relevant gene up-regulation that quickly returns to normal values. These changes differ between MDA-MB-231 and HBL-100 cells, highlighting the selectivity of the NAMI-A induced transcriptional perturbation in the invasive rather than in the non-tumorigenic cells. The transcriptional response, in the invasive MDA-MB-231 cells, comprises a set of early-response transcription factors and reveals a pharmacological signature in good agreement with the most peculiar NAMI-A behavior as a metastasis inhibitor such as cell cycle regulation and ECM remodeling. Globally, the results of this study indicate some transcription factors influencing the expression and activity of many downstream genes and proteins fundamentally involved in the functional effects of NAMI-A in vitro and in vivo.

[1]  J. Hoeijmakers,et al.  Deciphering the RNA landscape by RNAome sequencing , 2015, RNA biology.

[2]  David P. Kreil,et al.  A comprehensive assessment of RNA-seq accuracy, reproducibility and information content by the Sequencing Quality Control consortium , 2014, Nature Biotechnology.

[3]  W. Berger,et al.  NKP-1339, the first ruthenium-based anticancer drug on the edge to clinical application , 2014 .

[4]  Paola Chiarugi,et al.  Microenvironment and tumor cell plasticity: an easy way out. , 2013, Cancer letters.

[5]  Michael I Webb,et al.  EPR as a probe of the intracellular speciation of ruthenium(III) anticancer compounds. , 2013, Metallomics : integrated biometal science.

[6]  T. Oskarsson,et al.  The molecular composition of the metastatic niche. , 2013, Experimental cell research.

[7]  B. Leyland-Jones,et al.  Dissecting GRB7-mediated signals for proliferation and migration in HER2 overexpressing breast tumor cells: GTP-ase rules. , 2013, American journal of cancer research.

[8]  Silvia Pagliaretta,et al.  Role of maspin in cancer , 2013, Clinical and Translational Medicine.

[9]  B. Lai,et al.  Distinct cellular fates for KP1019 and NAMI-A determined by X-ray fluorescence imaging of single cells. , 2012, Metallomics : integrated biometal science.

[10]  A. Bergamo,et al.  CDK1 hyperphosphorylation maintenance drives the time-course of G2-M cell cycle arrest after short treatment with NAMI-A in Kb cells. , 2012, Anti-cancer agents in medicinal chemistry.

[11]  M. Buck,et al.  Plexin structures are coming: opportunities for multilevel investigations of semaphorin guidance receptors, their cell signaling mechanisms, and functions , 2012, Cellular and Molecular Life Sciences.

[12]  Young Yang,et al.  Berberine-induced AMPK activation inhibits the metastatic potential of melanoma cells via reduction of ERK activity and COX-2 protein expression. , 2012, Biochemical pharmacology.

[13]  A. Toker,et al.  NFAT promotes carcinoma invasive migration through glypican-6 , 2011, The Biochemical journal.

[14]  P. Dyson,et al.  Cellular uptake and subcellular distribution of ruthenium-based metallodrugs under clinical investigation versus cisplatin. , 2011, Metallomics : integrated biometal science.

[15]  L. Szmigiero,et al.  Proapoptotic activity in vitro of two novel ruthenium(II) complexes with flavanone-based ligands that overcome cisplatin resistance in human bladder carcinoma cells. , 2011, Journal of inorganic biochemistry.

[16]  E. Meggers.  From conventional to unusual enzyme inhibitor scaffolds: the quest for target specificity. , 2011, Angewandte Chemie.

[17]  A. Casini,et al.  Organometallic ruthenium-based antitumor compounds with novel modes of action , 2011 .

[18]  Lu-hua Zhang,et al.  Roles of GRP78 in physiology and cancer , 2010, Journal of cellular biochemistry.

[19]  A. Simpson,et al.  Dissecting the transcriptional networks underlying breast cancer: NR4A1 reduces the migration of normal and breast cancer cell lines , 2010, Breast Cancer Research.

[20]  E. Antonarakis,et al.  Ruthenium-based chemotherapeutics: are they ready for prime time? , 2010, Cancer Chemotherapy and Pharmacology.

[21]  X. Hao,et al.  Inhibition of prostate cancer by suicide gene targeting the FCY1 and HSV-TK genes. , 2009, Oncology reports.

[22]  P. Sadler,et al.  Current applications and future potential for bioinorganic chemistry in the development of anticancer drugs. , 2009, Drug discovery today.

[23]  Yasuhiro Shirakawa,et al.  Focal adhesion kinase as potential target for cancer therapy (Review). , 2009, Oncology reports.

[24]  C. Sirlin,et al.  A ruthenium-containing organometallic compound reduces tumor growth through induction of the endoplasmic reticulum stress gene CHOP. , 2009, Cancer research.

[25]  M. Saji,et al.  Regulator of calcineurin 1 modulates cancer cell migration in vitro , 2009, Clinical & Experimental Metastasis.

[26]  C. Molnar,et al.  Drosophila Axud1 is involved in the control of proliferation and displays pro-apoptotic activity , 2009, Mechanisms of Development.

[27]  Ying Su,et al.  Reproductive Biology and Endocrinology Open Access the Krüppel-like Factor 9 (klf9) Network in Hec-1-a Endometrial Carcinoma Cells Suggests the Carcinogenic Potential of Dys-regulated Klf9 Expression , 2022 .

[28]  B. Williams,et al.  Mapping and quantifying mammalian transcriptomes by RNA-Seq , 2008, Nature Methods.

[29]  Tsonwin Hai,et al.  A potential dichotomous role of ATF3, an adaptive-response gene, in cancer development , 2007, Oncogene.

[30]  M. Giphart-Gassler,et al.  A portrait of cisplatin-induced transcriptional changes in mouse embryonic stem cells reveals a dominant p53-like response. , 2007, Mutation research.

[31]  A. Bergamo,et al.  Ruthenium complexes can target determinants of tumour malignancy. , 2007, Dalton transactions.

[32]  C. Tanikawa,et al.  RGC32, a novel p53-inducible gene, is located on centrosomes during mitosis and results in G2/M arrest , 2007, Oncogene.

[33]  Robert Gentleman,et al.  Using GOstats to test gene lists for GO term association , 2007, Bioinform..

[34]  S. Gery,et al.  The circadian gene per1 plays an important role in cell growth and DNA damage control in human cancer cells. , 2006, Molecular cell.

[35]  A. Toker,et al.  NFAT Induces Breast Cancer Cell Invasion by Promoting the Induction of Cyclooxygenase-2* , 2006, Journal of Biological Chemistry.

[36]  G. Sava,et al.  Inhibition of B16 Melanoma Metastases with the Ruthenium Complex Imidazolium trans-Imidazoledimethylsulfoxide-tetrachlororuthenate and Down-Regulation of Tumor Cell Invasion , 2006, Journal of Pharmacology and Experimental Therapeutics.

[37]  T. Eling,et al.  The anti-invasive activity of cyclooxygenase inhibitors is regulated by the transcription factor ATF3 (activating transcription factor 3) , 2005, Molecular Cancer Therapeutics.

[38]  Zhimin Wei,et al.  Beta-catenin up-regulates the expression of cyclinD1, c-myc and MMP-7 in human pancreatic cancer: relationships with carcinogenesis and metastasis. , 2005, World journal of gastroenterology.

[39]  S. Antonarakis,et al.  Peutz–Jeghers LKB1 mutants fail to activate GSK-3β, preventing it from inhibiting Wnt signaling , 2005, Molecular Genetics and Genomics.

[40]  J. Schellens,et al.  A Phase I and Pharmacological Study with Imidazolium-trans-DMSO-imidazole-tetrachlororuthenate, a Novel Ruthenium Anticancer Agent , 2004, Clinical Cancer Research.

[41]  D. Osella,et al.  Electrochemical measurements confirm the preferential bonding of the antimetastatic complex [ImH][RuCl(4)(DMSO)(Im)] (NAMI-A) with proteins and the weak interaction with nucleobases. , 2004, Journal of inorganic biochemistry.

[42]  G. Sava,et al.  Actin-dependent tumour cell adhesion after short-term exposure to the antimetastasis ruthenium complex NAMI-A. , 2004, European journal of cancer.

[43]  Krister Wennerberg,et al.  Rho and Rac Take Center Stage , 2004, Cell.

[44]  Li Deng,et al.  Differential expression in SAGE: accounting for normal between-library variation , 2003, Bioinform..

[45]  M. Magnasco,et al.  Decay rates of human mRNAs: correlation with functional characteristics and sequence attributes. , 2003, Genome research.

[46]  J. Gregg,et al.  Allele-specific Holliday junction formation: a new mechanism of allelic discrimination for SNP scoring. , 2003, Genome research.

[47]  G. Pezzoni,et al.  Dual Action of NAMI-A in inhibition of solid tumor metastasis: selective targeting of metastatic cells and binding to collagen. , 2003, Clinical cancer research : an official journal of the American Association for Cancer Research.

[48]  S. Donnini,et al.  Antiangiogenic properties of selected ruthenium(III) complexes that are nitric oxide scavengers , 2003, British Journal of Cancer.

[49]  G. Sava,et al.  Inhibition of the MEK/ERK signaling pathway by the novel antimetastatic agent NAMI-A down regulates c-myc gene expression and endothelial cell proliferation. , 2002, European journal of biochemistry.

[50]  J. Cummings,et al.  In vitro and in vivo activity and cross resistance profiles of novel ruthenium (II) organometallic arene complexes in human ovarian cancer , 2002, British Journal of Cancer.

[51]  J. Uitto,et al.  Metastasis-associated protein (MTA)1 enhances migration, invasion, and anchorage-independent survival of immortalized human keratinocytes , 2002, Oncogene.

[52]  D. Ribatti,et al.  Inhibition of endothelial cell functions and of angiogenesis by the metastasis inhibitor NAMI-A , 2002, British Journal of Cancer.

[53]  Thomas D. Schmittgen,et al.  Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta Delta C(T)) Method. , 2001, Methods.

[54]  A. Bergamo,et al.  Tumour cell uptake G2-M accumulation and cytotoxicity of NAMI-A on TS/A adenocarcinoma cells. , 2001, Anticancer research.

[55]  A. Bergamo,et al.  Lack of In vitro cytotoxicity, associated to increased G(2)-M cell fraction and inhibition of matrigel invasion, may predict In vivo-selective antimetastasis activity of ruthenium complexes. , 2000, The Journal of pharmacology and experimental therapeutics.

[56]  A. Bergamo,et al.  Effects of NAMI-A and some related ruthenium complexes on cell viability after short exposure of tumor cells , 2000, Anti-cancer drugs.

[57]  J. Camonis,et al.  Interaction of the Grb7 adapter protein with Rnd1, a new member of the Rho family , 2000, FEBS letters.

[58]  J. Guan,et al.  Association of Focal Adhesion Kinase with Grb7 and Its Role in Cell Migration* , 1999, The Journal of Biological Chemistry.

[59]  A. Bergamo,et al.  In vitro cell cycle arrest, in vivo action on solid metastasizing tumors, and host toxicity of the antimetastatic drug NAMI-A and cisplatin. , 1999, The Journal of pharmacology and experimental therapeutics.

[60]  K. Mafune,et al.  A novel variant of human Grb7 is associated with invasive esophageal carcinoma. , 1998, The Journal of clinical investigation.

[61]  G. Sava,et al.  Pharmacological control of lung metastases of solid tumours by a novel ruthenium complex , 1998, Clinical & Experimental Metastasis.

[62]  M. Mattei,et al.  A New Member of the Rho Family, Rnd1, Promotes Disassembly of Actin Filament Structures and Loss of Cell Adhesion , 1998, The Journal of cell biology.

[63]  M. Schwartz,et al.  Integrin regulation of c-Abl tyrosine kinase activity and cytoplasmic-nuclear transport. , 1996, Proceedings of the National Academy of Sciences of the United States of America.

[64]  A. Bergamo,et al.  Down‐regulation of tumour gelatinase/inhibitor balance and preservation of tumour endothelium by an anti‐metastatic ruthenium complex , 1996, International journal of cancer.

[65]  E. Myers,et al.  Basic local alignment search tool. , 1990, Journal of molecular biology.

[66]  J. Schellens,et al.  Approaching tumour therapy beyond platinum drugs: status of the art and perspectives of ruthenium drug candidates. , 2012, Journal of inorganic biochemistry.

[67]  I. Rabinovitz,et al.  Use of RNA interference to inhibit integrin (α6β4)-mediated invasion and migration of breast carcinoma cells , 2004, Clinical & Experimental Metastasis.

[68]  A. Koleske,et al.  How do Abl family kinases regulate cell shape and movement? , 2004, Trends in cell biology.

[69]  A. Bergamo,et al.  Influence of chemical stability on the activity of the antimetastasis ruthenium compound NAMI-A. , 2002, European journal of cancer.